2-5A (pentasodium)

• Description :

  2-5A (5'-O-Triphosphoryladenylyl- (2'→5') -adenylyl- (2'→5') -adenosine) pentasodium is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A pentasodium is an immunotransmitter that fuels RNase L immunity. 2-5A pentasodium degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A pentasodium can be used in RSV and cancer research[1][2][3][4].

• Product Name Alternative :

  5'-O-Triphosphoryladenylyl- (2'→5') -adenylyl- (2'→5') -adenosine (pentasodium)

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis; RSV

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection; Inflammation/Immunology

• Concentration :

  100 mM * 50 μL in Water

• Smiles :

  NC1=NC=NC2=C1N=CN2[C@H]3[C@H](OP(OC[C@@H](O[C@H]([C@@H]4OP(OC[C@@H](O[C@H]([C@@H]5O)N6C=NC7=C6N=CN=C7N)[C@H]5O)(O[Na])=O)N8C=NC9=C8N=CN=C9N)[C@H]4O)(O[Na])=O)[C@H](O)[C@@H](COP(OP(OP(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)O3

• Molecular Formula :

  C30H35N15Na5O25P5

• Molecular Weight :

  1275.50

• References & Citations :

  [1]Kalinichenko EN, et al. 3'-Fluoro-3'-deoxy analogs of 2-5A 5'-monophosphate: binding to 2-5A-dependent endoribonuclease and susceptibility to (2'-5') phosphodiesterase degradation. Biochem Biophys Res Commun. 1990 Feb 28;167 (1) :20-6.|[2]Barnard DL, et al. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res. 1999 Apr;41 (3) :119-34.|[3]Wang S, Li L. 2-5A is an immunotransmitter that fuels RNase L immunity. Immunity. 2025 Apr 8;58 (4) :770-772. |[4]Huai W, et al. OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunity. Immunity. 2025 Apr 8;58 (4) :797-810.e6. doi: 10.1016/j.immuni.2025.01.016. Epub 2025 Feb 25.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Oligonucleotides

• Clinical Information :

  No Development Reported